Biocon share price rose 4.5% following US FDA clearance for its Malaysian insulin facility, resolving a regulatory bottleneck ...

Shares of Biocon surged as much as 5 per cent during the trading session on Monday after the USFDA cleared Malaysia unit to ...

Motilal Oswal is bullish on Biocon recommended buy rating on the stock with a target price of Rs 430 in its research report ...

Bengaluru: Biocon has announced that the U.S. Food and Drug Administration (FDA) has classified Biocon Biologics' Insulins ...

After the clearance from US drugs regulator, Motilal Oswal has upgraded Biocon to 'buy' with a target price of Rs 430 apiece.

Biocon’s share price climbed to an intraday high of Rs 377.50 per share in intraday trade on the Bombay Stock Exchange (BSE).

IREDA(Rs. 387.37 crore), TCS(Rs. 387.07 crore), Kalyan Jewellers Ind(Rs. 375.16 crore), Zomato(Rs. 373.61 crore), HDFC ...

Biocon jumped 4.03% to Rs 375.40 after the company said that the U.S. Food and Drug Administration (FDA) has classified Biocon Biologics' Insulins facilities in Johor Bahru, Malaysia as voluntary ...

Biocon shares increased by 4.5% after the US FDA classified its Malaysian insulin facilities as Voluntary Action Indicated.

Biocon has experienced a significant earnings decline over the past two years, led by a lack of potential approvals for the U ...

Clearance of Biocon's Malaysia unit puts an end to the drugmaker's regulatory hurdles and opens the door for the approval and ...

Shares of firms like HCL Tech, Dmart, Biocon, Waaree Energies, Power Grid, and others will be in focus on Monday's trade ...